Data Insights
By Company Name
No Filter Selected
By Disease Name
No Filter Selected
By Drug Name
No Filter Selected
By Themes
No Filter Selected
Showing 1 results out of 1
Data Insights
Trastuzumab by F. Hoffmann-La Roche for Ductal Carcinoma In Situ: Likelihood of Approval
Trastuzumab is under clinical development by F. Hoffmann-La Roche and currently in Phase III for Ductal Carcinoma In Situ. According...